NCT01502501撤回不适用
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Non-Ischemic Congestive Heart Failure Patients
Ageless Regenerative Institute1 个研究点 分布在 1 个国家开始时间: 2011年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Minnesota Living with Heart Failure Quality of Life Questionnaire
研究概览
简要总结
The intent of this clinical study is to answer the questions:
- Is the proposed treatment safe
- Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements indicating improvement, stability, or degradation of a patient's cardiovascular function and exercise capacity?
详细描述
This will be an open-label, non-randomized, multi-center patient-sponsored study designed to assess the safety and cardiovascular effects of Adipose-derived Stem Cell (ASC) implantation using a catheter delivery system in patients who have nonischemic congestive heart failure. A percutaneous transluminal endomyocardial injection catheter will be used for delivery of ASCs. The therapy is composed of cells isolated from a patient's own adipose tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to sign informed consent
- •Age >18 years and < 80 years
- •NYHA Class II-IV
- •Congestive Heart Failure without an acute coronary syndrome during the prior 6 months
- •LVEF less than or equal to 40% measured by echocardiography at both local and investigative sites, AND
- •Left ventricular wall without mural thrombus and of thickness greater than 0.5 cm
- •No significant valvular disease including: Moderate-to-severe mitral regurgitation (3-4+), aorticstenosis (valve area <1.5 cm2), aortic insufficiency (3-4+)
- •Up to date on all age and gender appropriate cancer screening per American Cancer Society
排除标准
- •Limiting symptoms due to non-CHF causes, such as lung disease, peripheral vascular disease, arthritis or other musculoskeletal disorders
- •Inability to complete a 6-minute walk test for any reason
- •Need for intravenous CHF medications, chronic continuous oxygen therapy or oral steroids,
- •Coronary Artery Bypass Surgery (CABG) surgery within 60 days prior to screening
- •Planned revascularization within 4 months following enrollment
- •Aortic aneurysm or dilatation (>3.8 cm by echocardiography or other imaging modality)
- •Peripheral vascular disease at or below the distal aorta that may interfere with catheter use
- •Hemodynamically significant pericardial disease
- •Prior aortic or mitral valve replacement
- •Biventricular pacing device implant within the last 3 months OR whose device is scheduled to be revised following enrollment in this trial
- •Scheduled to receive or history of cardiac transplant, surgical remodeling procedure, left ventricular assist device
- •Stroke within 180 days of screening
- •Positive pregnancy test in women of child bearing potential or who are unwilling to use an acceptable method of contraception.
- •Drug or alcohol dependence
- •Life expectancy of less than 1 year
- •History of cancer (other than non-melanoma skin cancer or in situ cervical cancer) in the last five years
- •Exposure to angiogenic therapy (including myocardial laser) or another investigational drug within 60 days of screening, or enrollment in any concurrent study that may confound the results of this study
- •Any factors in the opinion of the Investigator which render the patient unsuitable for participation, that will interfere with conduct of the study or interpretation of the results.
结局指标
主要结局
Minnesota Living with Heart Failure Quality of Life Questionnaire
时间窗: 6 months
Number of Adverse Events
时间窗: 6 months
Improvement in 6 minute walk test
时间窗: 6 months
Improvement in 6 minute walk test
时间窗: 3 months
compared to baseline
Minnesota Living with Heart Failure Quality of Life Questionnaire
时间窗: 3 months
次要结局
- Improvement in New York Heart Association (NYHA) classification(6 months)
- Improvement in the Left Ventricular Ejection Fraction (LVEF)(6 months)
- Improvement in the Left Ventricular (LV) Volume(6 months)
- Improvement in New York Heart Association (NYHA) classification(3 months)
- Improvement in the Left Ventricular Ejection Fraction (LVEF)(3 months)
- Improvement in the Left Ventricular (LV) Volume(3 months)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty SyndromeFrailty SyndromeNCT01501461Ageless Regenerative Institute
撤回
不适用
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple SclerosisAutoimmune Diseases of the Nervous SystemAutoimmune DiseasesNervous System DiseasesMultiple SclerosisNCT01453764Ageless Regenerative Institute
撤回
1 期
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After StrokeStrokeNCT01453829Ageless Regenerative Institute
撤回
不适用
Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's DiseaseParkinson's DiseaseNCT01453803Ageless Regenerative Institute
撤回
不适用
Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the BrainBrain Lesion (General)NCT01453777Ageless Regenerative Institute